Turner Pope IP protection....Affimer?18 Jul 2025 15:51
Avacta has three main interlinked IP families. Firstly, comes the foundational IP, which is the background platform IP of the pre|CISION® FAP-cleavable peptide drug conjugate that was exclusively licenced to Avacta by Bach Biosciences in 2018 (with the patent itself expiring in 2035). Secondly is the sustained release pre|CISION® mechanism that was invented and is wholly-owned by Avacta. The Board considers this technology, which opens up multiple different therapeutic options and opportunities for the Group, provides an effective reset for its entire portfolio (with its Program IP patent expiry in 2045). The third family is the pre|CISION® FAP-cleavable biologic drug conjugate IP, which is co-owned by Avacta and Tufts University, with Avacta having an exclusive sublicense to the technology (patent expiry 2041).